Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MedImmune, Micromet cancer deal

Under a co-development deal, Micromet (Munich, Germany) granted MedImmune (MEDI) North American development rights to its MT103 bispecific T cell

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE